Modulating cholesterol efflux capacity to improve cardiovascular disease

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Low high-density lipoprotein cholesterol (HDL-C) is linked to atherosclerotic cardiovascular disease (ASCVD).
• Therapies targeting HDL-C levels have not consistently reduced cardiovascular events.
• Focus has shifted to HDL function, particularly cholesterol efflux capacity (CEC).

Purpose of the Study:

• To review the impact of current medications and lifestyle interventions on CEC.
• To evaluate the potential of modulating CEC as a therapeutic strategy for cardiovascular risk reduction.

Main Methods:

• Systematic review of randomized controlled trials and observational studies.
• Analysis of medications including statins, fibrates, niacin, and novel agents.
• Inclusion of lifestyle interventions such as diet and exercise.

Main Results:

• Current cardiovascular medications and lifestyle interventions demonstrate variable effects on CEC.
• The impact of these interventions on CEC is influenced by study populations and assay methodologies.
• Evidence suggests CEC is a more reliable marker of cardiovascular risk than HDL-C levels alone.

Conclusions:

• Modulating CEC holds promise as a novel therapeutic target for improving cardiovascular risk profiles.
• Further research is needed to optimize interventions that enhance CEC for clinical benefit.
• Understanding CEC modulation is crucial for advancing cardiovascular disease prevention strategies.